Table 1.

Patient characteristics

CLL Pt. no.Sex/age (y)WBC (109/L)Lymph. %Hb. (g/dL)Plts. (109/L)Rai stageCD38+/ CD19+%β2M (mg/dL)VH mutationZAP- 70%StatusCytogeneticsPrevious treatment
1M/5873.79013.11281NA4.1Y80.9Alivet 12
2F/74102.28812.32361NA1.9NNAAliveNA
3F/8849.18512.21860NA3NDNAAliveD13
4M/6152.98414.812910.92.7NPos.Alivedel 11qFCR
5M/631438213164197.53Y33.3Alivedel 11qFCR
6F/701189412.5178162.53.2Y0Alivet 12Revlimid
7M/60133.59613.11130NA2.8N0Alivedel 13q
8F/5695.5971333402.12.4Y0AliveDip.
9F/7466.79412.52311NA1.8NDNAAliveNA
10F/75160.79012.1146114Y44.6Alivedel 13qFCR
11F/72136.69111.8244223.6YPos.Alivet 12Revlimid
12M/63969214.715500.33.5Y0Alivedel 13q
13M/6090.69114.71672NA4.8Y10.8Alivedel 13qFCR
14F/7026.49310.110130.23.2Y3.4Alivedel 13qRevlimid
15F/58172.69813.32121NA3.3Y0AliveNA
16F/7246.9799.8272324.7YPos.Alivet 12Revlimid
17F/60111.89212.72190NA3.5Y1.8AliveNARitux. GM
18F/7560.98912.51790NA3.5YNAAliveNA
19M/47130.98813258198.83.3Y46.2AliveNAFCR
20M/488.72015.21730NANANPos.AliveNACFAR
21F/58184.48813.62161NA2.7NNeg.AliveNA
22F/75258.99411.814011.14.2Y44.6Alivedel 13q

Abbreviations: WBC, white blood cells; lymph., lymphocytes; Hb., hemoglobin; Plts., platelets; β2M, β2 microglobulin; M, male; F, female; NA, not available; VH mutation, hypermutation of the immunoglobulin heavy chain gene presented as N (negative; if % derivation from the germline sequence is ≤2%) or Y (positive, if % derivation from germline sequence is >2%); Ritux., Rituxan; GM, granulocyte-macrophage colony-stimulating factor; FCR, cyclophosphamide, fludarabine, and rituxan; CFAR, cyclophosphamide, fludarabine, alemtuzumab, and rituxan; Pos., positive (analyzed by immunohistochemistry only); Neg., negative; t, translocation; del, deletion.